Endo International plc

Endo Pharmaceuticals Logo.png
Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology. The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.

In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion.

In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. However, Teva prevailed in this acquisition with a substantially higher bid.

This page was last edited on 5 April 2018, at 17:33.
Reference: https://en.wikipedia.org/wiki/Endo_International under CC BY-SA license.

Related Topics

Recently Viewed